None
Quote | Xeris Pharmaceuticals Inc. (NASDAQ:XERS)
Last: | $1.78 |
---|---|
Change Percent: | 1.15% |
Open: | $1.72 |
Close: | $1.78 |
High: | $1.84 |
Low: | $1.69 |
Volume: | 1,318,998 |
Last Trade Date Time: | 04/22/2024 03:00:00 am |
News | Xeris Pharmaceuticals Inc. (NASDAQ:XERS)
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
2024-03-30 01:28:53 ET Summary Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growt...
Message Board Posts | Xeris Pharmaceuticals Inc. (NASDAQ:XERS)
Subject | By | Source | When |
---|---|---|---|
Izzy Englander likes $XERS... | price_and_volume | investorshub | 05/27/2022 8:39:29 PM |
Anybody know what this is G85CVR010 ? It-showed-in-my-TD-acct-after | mess124 | investorshub | 01/20/2022 1:17:06 AM |
Yes indeed | Elgordo84 | investorshub | 12/31/2021 4:50:55 PM |
Nice catch in the low 2.00s. | alchemytrader | investorshub | 12/31/2021 1:22:50 PM |
Goodluck to all the Longs! | Elgordo84 | investorshub | 11/15/2021 2:41:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...